PACB stock: buy or sell?

PACB stock price: $5.71 -1.38% At close on August 22nd, 2019

Updated on:
August 22nd, 2019


Shares of Pacific Biosciences of California decreased an awful -1.38% and closed at $5.71. On August 13th PACB plummed a spooky -5.65%.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems.

Should I buy PACB stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, Pacific Biosciences of California stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean PACB will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Pacific Biosciences of California stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we collected 3 ratings published for PACB stock in the last month.

Is PACB a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-20Cantor Fitzgeraldn/aHold
2019-4-2StephensOverweightEqual Weight
2019-1-4CowenOutperformMarket Perform

PACB stock analysis

Daily outlook

Pacific Biosciences of California shares decreased -1.38% to $5.71 today.

Pacific Biosciences of California shares decreased -1.38% to $5.71 today.

PACB stock chart (daily)

Weekly outlook

Pacific Biosciences of California shares decreased -0.87% this week, ending at $5.71. By mid July PACB plummed a frightening -11.44% in just one week.

Since mid June, when PACB stock price broke down the 40-weeks moving avarage line, it slid $-1.18 per share (-17.13%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.

PACB stock chart (weekly)

PACB stock price history

PACB stock went public on October 27th, 2010 with a price of $16.501. Since then, PACB stock lost a -65.40%, with a yearly average of -8.20%.

1: Adjusted price after possible price splits or reverse-splits.

PACB stock historical price chart

PACB stock reached 52-week highs on November at $7.84, and all-time highs 2010-10-28 with a price of 17.47.

PACB stock price target is $8.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' PACB stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 2 price targets for PACB stock:
PACB stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-20Cantor FitzgeraldSet Price Targetn/a$8.00-
(in average)$0.00$8.000.0%
The price target for Pacific Biosciences of California stock is $8.00, moving in a range between $8.00 and $8.00. In average, analysts' outlook on PACB price target is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on April, Pacific Biosciences of California collapsed a hair-raising -22.73%. Unfortunately, reported EPS is not yet available in our database.
PACB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual sales report draw a scary slide of -15.88% to $78.63 million dollars. In the same way, its profit margin (compared to sales) plunged to -130.44%, that is $-102.56 million.

Pacific Biosciences of California fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Pacific Biosciences of California TTM sales up to were $59.26 and earnings $-78.38 M USD. If we compare this TTM figures with the last reported annuality, we can esteem Pacific Biosciences of California business evolution since December 2018: Annual turnover up to , compared to lastest yearly report, collapsed a hair-raising -24.63%. Regarding profit margin, Pacific Biosciences of California depreciated -1.82% to -130.44%

PACB annual Sales and Income evolution
2013$28 M-$-79.29 M-281.4%-
2014$61 M115.02%$-66.16 M-109.2%-16.56%
2015$93 M53.12%$-31.70 M-34.2%-52.09%
2016$91 M-2.23%$-74.38 M-82.0%134.65%
2017$93 M3.04%$-92.19 M-98.6%23.95%
2018$79 M-15.88%$-102.56 M-130.4%11.25%
TTM $59 M-24.63%$-78.38 M-132.3%-23.58%

Quarterly financial results

Pacific Biosciences of California reported M in revenues for 2019-Q1, a -100.00% less compared to previous quarter. Reported quarter earnings marked M with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was -157.73%. When comparing revenues to same quarter last year, Pacific Biosciences of California sales marked a spooky loss and plummed a -100.00%.
PACB quarterly Sales and Income evolution
2017-Q1$25 M-$-23.87 M-95.8%-
2017-Q2$20 M-19.46%$-25.54 M-127.3%7.00%
2017-Q3$24 M17.31%$-22.02 M-93.5%-13.78%
2017-Q4$25 M5.90%$-20.76 M-83.3%-5.72%
2018-Q1$19 M-22.35%$-24.18 M-124.9%16.46%
2018-Q2$22 M11.45%$-22.54 M-104.5%-6.78%
2018-Q3$18 M-15.84%$-25.04 M-137.9%11.11%
2018-Q4$20 M7.52%$-30.80 M-157.7%22.98%

Pacific Biosciences of California ownership

When you are planning to invest in a company, it's worth to check its ownership structure.

Pacific Biosciences of California shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 4.18% of all shares.

In case of Pacific Biosciences of California stock, 74.12% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for PACB stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Pacific Biosciences of California:

Market cap$871.8 M$235.1 M$71.2 B$42.4 B$918.0 M
Total shares152.7 M39.3 M8,730.0 M146.9 M45.0 M
Float shares141.1 M58.7 M8,720.0 M146.4 M36.4 M
  - Institutional holdings (%)74.1%55.4%58.6%91.9%86.4%
  - Insider holdings (%)4.2%0.9%0.2%0.4%4.8%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

PACB summary

Thursday, August 22nd, 2019
Day range$5.67 - $5.80
Previous close$5.79
Session gain-1.38%
Average true range$0.21
50d mov avg$5.82
100d mov avg$6.50
200d mov avg$6.93
Daily pattern
Weekly pattern lb06a

Pacific Biosciences of California performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We picked Fluidigm, General Electric, Illumina, Luminex, NanoString Technologies, PerkinElmer and Thermo Fisher Scientific as the bechmarking frame for Pacific Biosciences of California stock.
PACBPacific Bioscienc...-16.03%-22.52%33.10%
GEGeneral Electric-13.56%-16.39%-31.26%
NSTGNanoString Techno...-2.70%15.97%82.62%
TMOThermo Fisher Sci...2.45%10.53%18.89%

Pacific Biosciences of California competitors

One check before trading any stock is to review a list of its competitors, in this case for Pacific Biosciences of California. We chose 7 companies as Pacific Biosciences of California competitors as they are in the same industry or have similar market objectives.